U.S. Markets open in 4 hrs 53 mins

Janus Henderson Multi-Sector Income Fund Class S (JMUSX)

Nasdaq - Nasdaq Delayed Price. Currency in USD
Add to watchlist
10.090.00 (0.00%)
At close: 8:00PM EDT
Full screen
Previous Close10.09
YTD Return1.56%
Expense Ratio (net)1.14%
CategoryMultisector Bond
Last Cap Gain0.00
Morningstar Rating★★★★
Morningstar Risk RatingAbove Average
Sustainability RatingN/A
Net Assets2.86B
Beta (5Y Monthly)0.75
Yield4.21%
5y Average ReturnN/A
Holdings Turnover188.00%
Last Dividend0.04
Average for CategoryN/A
Inception DateFeb 28, 2014
  • Neovasc to Report Fourth Quarter and Fiscal Year 2020 Results on March 11, 2021
    GlobeNewswire

    Neovasc to Report Fourth Quarter and Fiscal Year 2020 Results on March 11, 2021

    VANCOUVER and MINNEAPOLIS, March 04, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (NASDAQ, TSX: NVCN) will report results for the fourth quarter and fiscal year ended December 31, 2020 after the market close on Thursday, March 11, 2021. Neovasc President and Chief Executive Officer Fred Colen and Chief Financial Officer Chris Clark will host a conference call to review the Company’s results at 4:30 pm EST. Interested parties may access the conference call by dialing (877) 407-9208 or (201) 493-6784 (International). Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc website at https://www.neovasc.com/investors/. A replay of the webcast will be available approximately 30 minutes after the conclusion of the call using the link on the Neovasc website. About Neovasc Inc. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. The Company is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States (2 U.S. patients have been treated under Compassionate Use) and has been commercially available in Europe since 2015, and Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com. Investors Mike Cavanaugh Westwicke/ICR Phone: +1.646.877.9641 Mike.Cavanaugh@westwicke.com Media Sean Leous Westwicke/ICR Phone: +1.646.677.1839 Sean.Leous@icrinc.com Forward-Looking Statement Disclaimer Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words "expect", "anticipate", "estimate", "may", "will", "should", "intend," "believe", and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to the expansion of its product range and the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the "Risk Factors" section of the Company's Annual Report on Form 20-F and in the Management's Discussion and Analysis for the three and nine months ended September 30, 2020 (copies of which may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on the Company's forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

  • Neovasc to Participate in 2021 H.C. Wainwright Global Life Sciences Conference
    Newsfile

    Neovasc to Participate in 2021 H.C. Wainwright Global Life Sciences Conference

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 3, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), today announced that company management will be participating in the 2021 H.C. Wainwright Global Life Sciences Conference that is scheduled to take place March 9-10, 2021. A recorded presentation by Bill Little, Neovasc's Chief Operating Officer, will be available on the Conference website starting at 7:00 am EST on March 9. Company management will also ...

  • Neovasc Comments on Clinical Cardiology Journal Publication
    Newsfile

    Neovasc Comments on Clinical Cardiology Journal Publication

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 2, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the journal Clinical Cardiology has published an article entitled, "Long-term outcomes of patients undergoing coronary sinus reducer implantation - A multicenter study."The article, authored by Maayan Konigstein, M.D., Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Israel describes the long-term outcomes in 99 patients ...